Companies: 10,795·Total market cap: $144.5T
Erasca, Inc.

Erasca, Inc.

ERASNASDAQHealthcare● Active
$12.87
+$0.90(+7.52%)
Market Cap$4.0B
P/E Ratio—
52W High$24.28
52W Low$1.21
Cash on HandFinancialsRevenue

Erasca, Inc. (ERAS) Cash on Hand — Cash & Short-Term Investments

Cash & cash equivalents plus short-term investments from the balance sheet, YoY change, and net cash vs debt context.

ERAS · cash on hand · updated Dec 31, 2025

Core cash position

Cash & Short-Term Investments (CCE + ST Investments)
$276.1M▼ -7.5% vs prior year
FY · as of Dec 31, 2025 · Reported in USD
Cash & Cash Equiv. (CCE)
$73.8M
cashAndCashEquivalents
Short-Term Investments
$202.3M
shortTermInvestments
YoY Change vs Prior Year
-7.5%
vs prior fiscal year
Latest Quarter
$243.8M
Q1 2026
Data Scope & Methodology

Cash on Hand = Cash & Cash Equivalents (CCE) + Short-Term Investments, as reported on the balance sheet (10-K/10-Q). Also referred to as cash reserves or cash position. Not free cash flow.

Source: FMP /balance-sheet-statement · SEC 10-K / 10-Q · Reported in USD

Source: FMP /balance-sheet-statement · SEC 10-K / 10-Q · USDUpdated: December 31, 2025

Net cash vs debt

Cash & ST Investments$276.1MCash on Hand
Total Debt$47.1MTotal Debt
Net Cash / Net Debt+$228.9MNet Cash Position
Cash vs Debt Ratio
Cash 85%Debt 15%

Erasca, Inc. has a net cash position of $228.9M, holding more cash than debt.

Net Cash = Cash & ST Investments − Total Debt$276.1M − $47.1M = +$228.9M

Cash on hand history

YoY Increase
YoY Decrease
Latest Year
ERAS annual cash on hand history · Cash & Short-Term Investments · Source: FMP /balance-sheet-statement

Annual cash on hand by year

DateCash & ST InvestmentsYoY Change
Dec 31, 2025Latest$276.1M-7.5%
Dec 31, 2024$298.3M-4.5%
Dec 31, 2023$312.4M-28.3%
Dec 31, 2022$435.6M+5.1%
Dec 31, 2021$414.5M+249.2%
ERAS cash on hand annual historical data · Cash & Short-Term Investments per balance sheet (10-K/10-Q) · Reported in USD · Source: FMP /balance-sheet-statement

Healthcare Sector Cash Reserves Comparison

#CompanyCash & ST Inv.Cash/MCap
#1
UnitedHealth Group Incorporated
UnitedHealth Group Incorporated
UNH
$28.12B7.6%#2
Johnson & Johnson
Johnson & Johnson
JNJ
$20.10B3.6%#3
Eli Lilly and Company
Eli Lilly and Company
LLY
$7.27B0.7%#4
AbbVie Inc.
AbbVie Inc.
ABBV
$5.26B1.3%
#5
Erasca, Inc.
Erasca, Inc.YOU
ERAS
$276.1M6.9%
Healthcare sector cash reserves · Source: FMP /balance-sheet-statement + /profile · Sorted by Cash desccompanies with most cash on hand →

About cash on hand & methodology

Erasca, Inc. (ERAS) cash on hand as of December 31, 2025 is $276.1M, comprising $73.8M in cash and cash equivalents (CCE) plus $202.3M in short-term investments — reported as Erasca, Inc. cash and short-term investments on the balance sheet (10-K filing). Also referred to as Erasca, Inc. cash reserves or cash position.

Erasca, Inc. annual cash on hand history shows decreased -7.5% in 2025: decreased -7.5% in 2025. Erasca, Inc. cash reserves in 2025 reflect the company's capital allocation strategy.

Erasca, Inc. carries total debt of $47.1M against cash of $276.1M, resulting in a net cash position of +$228.9M. For the full balance sheet, see the Financials → Balance Sheet tab.

Figures tie to SEC 10-K/10-Q balance sheet disclosures and FMP /balance-sheet-statement where noted.
Financial statementsFree cash flowNet incomeRevenueMarket capP/E ratioEarningsPrice history

Frequently asked questions

ERAS cash on hand · 5 questions

As of December 31, 2025, Erasca, Inc. (ERAS) has $276,075,000 in cash on hand — defined as cash and short-term investments on the balance sheet. This includes $73,805,000 in cash and cash equivalents (CCE) plus $202,270,000 in short-term investments. Latest quarter (March 31, 2026): $243,788,000. Data sourced from the annual 10-K filing via FMP.

ERAS cash on handERAS cash reservesERAS cash 2025how much cash does ERAS have

▸ Source: FMP /balance-sheet-statement · US GAAP · Erasca, Inc. · Erasca, Inc. SEC 10-K & 10-Q filings · US GAAP · Last updated: December 31, 2025